This protocol is judged by an institutional review board, an impartial group that critiques any scientific trials involving individuals. If a review requires a Agenda I drug, as soon as the board approves the protocol as ethical, the researchers really have to make an application for an investigational new drug (IND) selection with the FDA.Weiser